| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fanconi Anemia | 113 | 2024 | 324 | 18.620 |
Why?
|
| DNA Repair | 94 | 2024 | 2043 | 9.380 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 57 | 2021 | 146 | 4.990 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 38 | 2021 | 97 | 4.930 |
Why?
|
| DNA Replication | 32 | 2024 | 1414 | 4.310 |
Why?
|
| DNA Damage | 74 | 2024 | 2445 | 4.160 |
Why?
|
| BRCA1 Protein | 35 | 2024 | 1149 | 4.100 |
Why?
|
| Cell Cycle Proteins | 42 | 2024 | 3447 | 4.090 |
Why?
|
| DNA Breaks, Double-Stranded | 17 | 2023 | 612 | 3.500 |
Why?
|
| Nuclear Proteins | 64 | 2021 | 5789 | 3.480 |
Why?
|
| Ovarian Neoplasms | 34 | 2024 | 4849 | 2.800 |
Why?
|
| DNA-Binding Proteins | 66 | 2023 | 9586 | 2.790 |
Why?
|
| Endopeptidases | 19 | 2016 | 774 | 2.770 |
Why?
|
| Fanconi Anemia Complementation Group A Protein | 16 | 2024 | 50 | 2.240 |
Why?
|
| Receptors, Erythropoietin | 45 | 2001 | 144 | 2.210 |
Why?
|
| Ubiquitin | 30 | 2014 | 839 | 2.160 |
Why?
|
| DNA-Directed DNA Polymerase | 11 | 2023 | 484 | 2.100 |
Why?
|
| DNA, Single-Stranded | 5 | 2024 | 353 | 1.760 |
Why?
|
| Erythropoietin | 35 | 2001 | 719 | 1.730 |
Why?
|
| Genomic Instability | 20 | 2021 | 709 | 1.720 |
Why?
|
| BRCA2 Protein | 17 | 2024 | 797 | 1.650 |
Why?
|
| HeLa Cells | 35 | 2024 | 3088 | 1.610 |
Why?
|
| Proliferating Cell Nuclear Antigen | 13 | 2019 | 283 | 1.560 |
Why?
|
| Genes, BRCA1 | 12 | 2022 | 753 | 1.330 |
Why?
|
| Pyrazines | 11 | 2024 | 1202 | 1.250 |
Why?
|
| DNA | 30 | 2023 | 7196 | 1.240 |
Why?
|
| Hematopoietic Stem Cells | 19 | 2021 | 3394 | 1.240 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2024 | 5304 | 1.230 |
Why?
|
| DNA Helicases | 11 | 2021 | 851 | 1.230 |
Why?
|
| Signal Transduction | 56 | 2024 | 23415 | 1.210 |
Why?
|
| Mitomycin | 24 | 2010 | 263 | 1.190 |
Why?
|
| Genes, BRCA2 | 10 | 2022 | 590 | 1.180 |
Why?
|
| Ubiquitins | 11 | 2016 | 366 | 1.160 |
Why?
|
| Cell Cycle | 19 | 2016 | 2929 | 1.150 |
Why?
|
| Proteins | 28 | 2012 | 6030 | 1.110 |
Why?
|
| Ubiquitination | 17 | 2021 | 1006 | 1.080 |
Why?
|
| Cystadenocarcinoma, Serous | 6 | 2022 | 473 | 1.080 |
Why?
|
| Neoplasms | 26 | 2023 | 22131 | 1.060 |
Why?
|
| Protein Binding | 36 | 2024 | 9345 | 1.020 |
Why?
|
| Cisplatin | 14 | 2020 | 1650 | 0.950 |
Why?
|
| Glycoside Hydrolases | 1 | 2024 | 135 | 0.930 |
Why?
|
| Multiprotein Complexes | 8 | 2024 | 1118 | 0.930 |
Why?
|
| Phosphoproteins | 7 | 2024 | 2445 | 0.900 |
Why?
|
| Cell Line | 70 | 2020 | 15577 | 0.890 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 14 | 2018 | 21 | 0.890 |
Why?
|
| Animals | 148 | 2024 | 168202 | 0.890 |
Why?
|
| Bone Marrow | 9 | 2021 | 2909 | 0.880 |
Why?
|
| Cell Nucleus | 16 | 2023 | 2894 | 0.870 |
Why?
|
| Mutation | 50 | 2024 | 30015 | 0.850 |
Why?
|
| Multienzyme Complexes | 5 | 2011 | 666 | 0.840 |
Why?
|
| Fanconi Anemia Complementation Group G Protein | 12 | 2018 | 18 | 0.840 |
Why?
|
| Recombination, Genetic | 12 | 2021 | 1519 | 0.840 |
Why?
|
| Ataxia Telangiectasia | 2 | 2020 | 107 | 0.830 |
Why?
|
| Ubiquitin Thiolesterase | 6 | 2016 | 455 | 0.810 |
Why?
|
| Exodeoxyribonucleases | 5 | 2021 | 191 | 0.800 |
Why?
|
| Cell Line, Tumor | 39 | 2024 | 16968 | 0.780 |
Why?
|
| Immediate-Early Proteins | 7 | 2001 | 444 | 0.780 |
Why?
|
| Protein Processing, Post-Translational | 15 | 2020 | 1971 | 0.780 |
Why?
|
| Genetic Complementation Test | 18 | 2016 | 555 | 0.770 |
Why?
|
| Pyrazoles | 6 | 2021 | 2008 | 0.760 |
Why?
|
| Chromatin | 14 | 2021 | 2955 | 0.760 |
Why?
|
| Ubiquitin-Protein Ligases | 10 | 2020 | 1894 | 0.750 |
Why?
|
| Humans | 287 | 2024 | 760740 | 0.740 |
Why?
|
| RNA Splicing | 3 | 2024 | 898 | 0.740 |
Why?
|
| Mice | 96 | 2024 | 81368 | 0.730 |
Why?
|
| Arabidopsis Proteins | 11 | 2013 | 264 | 0.730 |
Why?
|
| Interleukin-3 | 15 | 2003 | 425 | 0.720 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2020 | 44 | 0.720 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2017 | 789 | 0.710 |
Why?
|
| Chromatin Assembly and Disassembly | 3 | 2014 | 634 | 0.700 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2022 | 725 | 0.690 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2020 | 68 | 0.690 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2022 | 2916 | 0.680 |
Why?
|
| S Phase | 12 | 2016 | 421 | 0.670 |
Why?
|
| Cross-Linking Reagents | 11 | 2016 | 685 | 0.670 |
Why?
|
| DNA Repair-Deficiency Disorders | 2 | 2018 | 37 | 0.660 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2024 | 1135 | 0.640 |
Why?
|
| Phthalazines | 8 | 2023 | 383 | 0.640 |
Why?
|
| Gene Expression Regulation | 19 | 2012 | 11874 | 0.620 |
Why?
|
| Viral Envelope Proteins | 12 | 2000 | 640 | 0.610 |
Why?
|
| Transfection | 36 | 2016 | 5765 | 0.600 |
Why?
|
| Receptors, Cell Surface | 19 | 1992 | 2802 | 0.590 |
Why?
|
| Endonucleases | 3 | 2019 | 371 | 0.580 |
Why?
|
| Trans-Activators | 10 | 2021 | 2851 | 0.580 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2021 | 4021 | 0.570 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2024 | 3599 | 0.570 |
Why?
|
| Embryo Loss | 2 | 2015 | 55 | 0.570 |
Why?
|
| Anus Neoplasms | 2 | 2021 | 329 | 0.560 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2015 | 487 | 0.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2023 | 11735 | 0.560 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2020 | 630 | 0.550 |
Why?
|
| HEK293 Cells | 10 | 2024 | 4269 | 0.550 |
Why?
|
| Transforming Growth Factor beta | 4 | 2022 | 1962 | 0.540 |
Why?
|
| Gene Expression Regulation, Neoplastic | 19 | 2021 | 8542 | 0.540 |
Why?
|
| Hematopoiesis | 7 | 2020 | 2049 | 0.540 |
Why?
|
| Carrier Proteins | 8 | 2020 | 4937 | 0.540 |
Why?
|
| Friend murine leukemia virus | 6 | 2000 | 37 | 0.530 |
Why?
|
| DNA Repair Enzymes | 3 | 2021 | 346 | 0.530 |
Why?
|
| Protein Kinases | 5 | 2012 | 1606 | 0.530 |
Why?
|
| Chromosomal Instability | 7 | 2016 | 178 | 0.530 |
Why?
|
| Aldehydes | 1 | 2017 | 170 | 0.530 |
Why?
|
| Amino Acid Sequence | 36 | 2020 | 13442 | 0.520 |
Why?
|
| Cell Survival | 13 | 2020 | 5780 | 0.520 |
Why?
|
| Cell Line, Transformed | 15 | 2007 | 866 | 0.520 |
Why?
|
| Rad51 Recombinase | 8 | 2015 | 189 | 0.510 |
Why?
|
| Organoids | 2 | 2019 | 744 | 0.500 |
Why?
|
| Poly(ADP-ribose) Polymerases | 7 | 2020 | 426 | 0.500 |
Why?
|
| Protein-Tyrosine Kinases | 17 | 2020 | 2425 | 0.490 |
Why?
|
| Cloning, Molecular | 20 | 2012 | 4172 | 0.490 |
Why?
|
| Antineoplastic Agents | 15 | 2023 | 13635 | 0.480 |
Why?
|
| Ultraviolet Rays | 15 | 2019 | 1079 | 0.480 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2020 | 2896 | 0.480 |
Why?
|
| Phosphorylation | 26 | 2020 | 8311 | 0.470 |
Why?
|
| Fanconi Anemia Complementation Group E Protein | 4 | 2014 | 4 | 0.470 |
Why?
|
| Molecular Sequence Data | 43 | 2014 | 17630 | 0.460 |
Why?
|
| Endodeoxyribonucleases | 5 | 2024 | 164 | 0.450 |
Why?
|
| DNA, Neoplasm | 2 | 2018 | 1743 | 0.440 |
Why?
|
| Novobiocin | 2 | 2023 | 35 | 0.430 |
Why?
|
| Germ-Line Mutation | 7 | 2020 | 1852 | 0.430 |
Why?
|
| Nucleotidyltransferases | 2 | 2012 | 244 | 0.420 |
Why?
|
| Mitosis | 7 | 2024 | 1187 | 0.420 |
Why?
|
| Chickens | 6 | 2014 | 858 | 0.420 |
Why?
|
| Proto-Oncogene Proteins | 13 | 2009 | 4512 | 0.410 |
Why?
|
| Lymphocytes | 10 | 2009 | 2604 | 0.410 |
Why?
|
| RNA, Small Interfering | 15 | 2021 | 3419 | 0.410 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2010 | 1169 | 0.410 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 899 | 0.400 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 3 | 2018 | 106 | 0.400 |
Why?
|
| Killer Cells, Natural | 10 | 2000 | 2191 | 0.390 |
Why?
|
| Adenosine Triphosphatases | 4 | 2023 | 835 | 0.390 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2013 | 2821 | 0.390 |
Why?
|
| Spleen Focus-Forming Viruses | 5 | 1994 | 16 | 0.380 |
Why?
|
| Radiation, Ionizing | 5 | 2013 | 251 | 0.380 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2011 | 68 | 0.380 |
Why?
|
| Pancreatic Neoplasms | 4 | 2023 | 5369 | 0.380 |
Why?
|
| Receptors, Immunologic | 6 | 1998 | 1409 | 0.370 |
Why?
|
| Microsatellite Instability | 4 | 2019 | 716 | 0.370 |
Why?
|
| Deoxycytidine | 5 | 2024 | 878 | 0.370 |
Why?
|
| Leukemia, Erythroblastic, Acute | 8 | 2000 | 176 | 0.360 |
Why?
|
| Mutagens | 5 | 2016 | 179 | 0.360 |
Why?
|
| Bloom Syndrome | 2 | 2009 | 10 | 0.350 |
Why?
|
| Cell Division | 21 | 2003 | 4457 | 0.350 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2872 | 0.350 |
Why?
|
| Breast Neoplasms | 13 | 2020 | 20988 | 0.350 |
Why?
|
| Fibroblasts | 15 | 2020 | 4140 | 0.350 |
Why?
|
| Gene Deletion | 5 | 2013 | 2659 | 0.350 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 9277 | 0.340 |
Why?
|
| Fanconi Anemia Complementation Group L Protein | 4 | 2014 | 6 | 0.340 |
Why?
|
| Enzyme Inhibitors | 7 | 2015 | 3705 | 0.340 |
Why?
|
| Histones | 2 | 2017 | 2577 | 0.330 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 7 | 2007 | 7 | 0.330 |
Why?
|
| Gene Knockdown Techniques | 7 | 2018 | 1608 | 0.330 |
Why?
|
| Cells, Cultured | 25 | 2020 | 18937 | 0.330 |
Why?
|
| Cytokinesis | 1 | 2010 | 169 | 0.330 |
Why?
|
| Chromosome Breakage | 9 | 2016 | 159 | 0.330 |
Why?
|
| RNA-Binding Proteins | 7 | 2017 | 1890 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2024 | 5672 | 0.320 |
Why?
|
| Bone Marrow Cells | 4 | 2010 | 2409 | 0.320 |
Why?
|
| DNA, Complementary | 10 | 2005 | 1989 | 0.320 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 1056 | 0.320 |
Why?
|
| Female | 77 | 2024 | 392203 | 0.310 |
Why?
|
| Curcumin | 2 | 2007 | 98 | 0.310 |
Why?
|
| Models, Biological | 13 | 2012 | 9461 | 0.300 |
Why?
|
| CDC2 Protein Kinase | 3 | 2011 | 213 | 0.300 |
Why?
|
| RNA Interference | 8 | 2019 | 2829 | 0.300 |
Why?
|
| Zinc Fingers | 2 | 2010 | 578 | 0.300 |
Why?
|
| Glutathione Transferase | 3 | 2010 | 565 | 0.300 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2013 | 2803 | 0.300 |
Why?
|
| Piperazines | 5 | 2022 | 2521 | 0.300 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 785 | 0.290 |
Why?
|
| Milk Proteins | 5 | 2001 | 162 | 0.290 |
Why?
|
| Transcription Factors | 11 | 2021 | 12116 | 0.290 |
Why?
|
| Radiation Tolerance | 5 | 2019 | 478 | 0.290 |
Why?
|
| Point Mutation | 6 | 2015 | 1595 | 0.290 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 1754 | 0.290 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 6345 | 0.290 |
Why?
|
| Isoxazoles | 3 | 2024 | 232 | 0.280 |
Why?
|
| Erythropoiesis | 8 | 2002 | 684 | 0.280 |
Why?
|
| Head and Neck Neoplasms | 2 | 2019 | 2894 | 0.270 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2009 | 617 | 0.270 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 2020 | 0.270 |
Why?
|
| Interleukin-2 | 11 | 2001 | 1888 | 0.270 |
Why?
|
| Base Sequence | 26 | 2018 | 12420 | 0.270 |
Why?
|
| Microsatellite Repeats | 2 | 2019 | 783 | 0.260 |
Why?
|
| Proteasome Endopeptidase Complex | 7 | 2015 | 1320 | 0.260 |
Why?
|
| Mutation, Missense | 6 | 2018 | 2570 | 0.250 |
Why?
|
| RNA, Messenger | 21 | 2024 | 12759 | 0.250 |
Why?
|
| Protease Inhibitors | 3 | 2016 | 753 | 0.250 |
Why?
|
| Models, Genetic | 7 | 2019 | 3431 | 0.250 |
Why?
|
| Growth Inhibitors | 2 | 1997 | 375 | 0.250 |
Why?
|
| Mice, Knockout | 10 | 2021 | 14388 | 0.240 |
Why?
|
| G2 Phase | 4 | 2002 | 136 | 0.240 |
Why?
|
| Mice, Nude | 6 | 2018 | 3606 | 0.240 |
Why?
|
| HLA-B Antigens | 3 | 1997 | 317 | 0.240 |
Why?
|
| Enhancer Elements, Genetic | 4 | 2001 | 1360 | 0.240 |
Why?
|
| Multigene Family | 6 | 2000 | 1076 | 0.240 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2000 | 1834 | 0.240 |
Why?
|
| Apoptosis | 7 | 2021 | 9476 | 0.240 |
Why?
|
| Cyclin B1 | 1 | 2024 | 58 | 0.240 |
Why?
|
| Interleukins | 7 | 1994 | 783 | 0.240 |
Why?
|
| Models, Molecular | 9 | 2024 | 5433 | 0.230 |
Why?
|
| Erythroid Precursor Cells | 4 | 1994 | 212 | 0.230 |
Why?
|
| Exons | 6 | 2024 | 2381 | 0.230 |
Why?
|
| Cell Death | 5 | 2019 | 1677 | 0.230 |
Why?
|
| Cell Proliferation | 6 | 2021 | 10429 | 0.230 |
Why?
|
| Drug Resistance | 5 | 2018 | 1594 | 0.230 |
Why?
|
| Xenopus | 2 | 2020 | 711 | 0.230 |
Why?
|
| Spliceosomes | 1 | 2024 | 119 | 0.220 |
Why?
|
| Rosaniline Dyes | 1 | 2023 | 50 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2024 | 112 | 0.220 |
Why?
|
| Binding Sites | 7 | 2018 | 6051 | 0.220 |
Why?
|
| Brain Neoplasms | 4 | 2024 | 9026 | 0.220 |
Why?
|
| Protein Structure, Tertiary | 7 | 2014 | 3793 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 8 | 2021 | 6126 | 0.220 |
Why?
|
| DNA-Activated Protein Kinase | 2 | 2022 | 112 | 0.220 |
Why?
|
| Phenotype | 16 | 2016 | 16572 | 0.220 |
Why?
|
| RNA Precursors | 1 | 2024 | 200 | 0.210 |
Why?
|
| Bone Marrow Diseases | 2 | 2002 | 233 | 0.210 |
Why?
|
| Repressor Proteins | 1 | 2014 | 2985 | 0.210 |
Why?
|
| Receptors, Interleukin-3 | 4 | 1997 | 29 | 0.210 |
Why?
|
| Echocardiography, Stress | 1 | 2003 | 134 | 0.210 |
Why?
|
| Transposases | 1 | 2022 | 104 | 0.200 |
Why?
|
| Genes, Immediate-Early | 3 | 1997 | 102 | 0.200 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2023 | 1727 | 0.200 |
Why?
|
| Receptors, Interleukin-2 | 6 | 2000 | 561 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2021 | 3611 | 0.200 |
Why?
|
| Blotting, Western | 7 | 2016 | 5034 | 0.200 |
Why?
|
| Gene Silencing | 7 | 2017 | 1503 | 0.190 |
Why?
|
| Glioblastoma | 3 | 2011 | 3481 | 0.190 |
Why?
|
| Mutagenesis | 5 | 2011 | 1230 | 0.190 |
Why?
|
| Interleukin-12 | 7 | 1995 | 577 | 0.190 |
Why?
|
| Colony-Forming Units Assay | 1 | 2021 | 351 | 0.190 |
Why?
|
| Neoplasm Proteins | 6 | 2018 | 3607 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2020 | 17878 | 0.190 |
Why?
|
| Down-Regulation | 4 | 2016 | 2916 | 0.190 |
Why?
|
| G1 Phase | 4 | 2014 | 403 | 0.190 |
Why?
|
| Protein Biosynthesis | 3 | 1999 | 2100 | 0.190 |
Why?
|
| Homozygote | 5 | 2013 | 1776 | 0.180 |
Why?
|
| Pyridazines | 1 | 2022 | 201 | 0.180 |
Why?
|
| Ficusin | 1 | 2020 | 15 | 0.180 |
Why?
|
| Sequence Homology, Amino Acid | 7 | 2012 | 2747 | 0.180 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 3 | 2014 | 110 | 0.180 |
Why?
|
| HSP90 Heat-Shock Proteins | 3 | 2021 | 424 | 0.180 |
Why?
|
| RecQ Helicases | 2 | 2010 | 53 | 0.180 |
Why?
|
| T-Lymphocytes | 9 | 2001 | 10175 | 0.170 |
Why?
|
| Recombinant Proteins | 16 | 2018 | 6520 | 0.170 |
Why?
|
| Leukemia, Experimental | 5 | 1997 | 225 | 0.170 |
Why?
|
| Lysophospholipids | 1 | 2022 | 337 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2016 | 1088 | 0.170 |
Why?
|
| Retroviridae | 5 | 2006 | 851 | 0.170 |
Why?
|
| Heterozygote | 4 | 2017 | 2780 | 0.170 |
Why?
|
| Polycythemia Vera | 3 | 2005 | 161 | 0.170 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 161 | 0.160 |
Why?
|
| Alleles | 9 | 2016 | 6861 | 0.160 |
Why?
|
| Leiomyosarcoma | 1 | 2023 | 422 | 0.160 |
Why?
|
| Flap Endonucleases | 1 | 2019 | 17 | 0.160 |
Why?
|
| Immunoblotting | 6 | 2011 | 1646 | 0.160 |
Why?
|
| Telomere-Binding Proteins | 1 | 2020 | 119 | 0.160 |
Why?
|
| Cell Transformation, Viral | 3 | 2001 | 526 | 0.160 |
Why?
|
| Cytoplasmic Dyneins | 1 | 2018 | 24 | 0.160 |
Why?
|
| Genes, Neoplasm | 2 | 2017 | 370 | 0.160 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2018 | 110 | 0.160 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2019 | 72 | 0.160 |
Why?
|
| Sequence Deletion | 6 | 2012 | 1490 | 0.160 |
Why?
|
| Up-Regulation | 5 | 2016 | 4117 | 0.160 |
Why?
|
| Genes, Lethal | 1 | 2019 | 223 | 0.150 |
Why?
|
| Interferon Type I | 1 | 2022 | 557 | 0.150 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 218 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 9 | 2021 | 22117 | 0.150 |
Why?
|
| Microscopy, Fluorescence | 5 | 2008 | 2639 | 0.150 |
Why?
|
| Receptors, KIR | 6 | 1998 | 110 | 0.150 |
Why?
|
| Pyrimidinones | 1 | 2020 | 385 | 0.150 |
Why?
|
| Immunotherapy | 3 | 2018 | 4642 | 0.150 |
Why?
|
| Hematopoietic Cell Growth Factors | 2 | 1994 | 98 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2021 | 5319 | 0.150 |
Why?
|
| Carboplatin | 2 | 2018 | 793 | 0.150 |
Why?
|
| Mouth Mucosa | 2 | 2019 | 432 | 0.150 |
Why?
|
| DNA Primers | 5 | 2008 | 2817 | 0.150 |
Why?
|
| Interleukin-4 | 3 | 2000 | 1146 | 0.150 |
Why?
|
| Cells | 1 | 1999 | 164 | 0.150 |
Why?
|
| RNA Helicases | 1 | 2018 | 143 | 0.140 |
Why?
|
| Kinetics | 9 | 2016 | 6370 | 0.140 |
Why?
|
| Chromosome Aberrations | 6 | 2018 | 1768 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2000 | 799 | 0.140 |
Why?
|
| Receptors, Cytokine | 2 | 1996 | 257 | 0.140 |
Why?
|
| Isoenzymes | 1 | 2001 | 1687 | 0.140 |
Why?
|
| Janus Kinase 2 | 8 | 2005 | 560 | 0.140 |
Why?
|
| Platinum | 4 | 2020 | 220 | 0.140 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 3868 | 0.140 |
Why?
|
| Models, Chemical | 1 | 1999 | 611 | 0.140 |
Why?
|
| Lymphocyte Activation | 6 | 2000 | 5463 | 0.140 |
Why?
|
| Ligases | 1 | 1998 | 333 | 0.130 |
Why?
|
| Interferon-gamma | 7 | 2000 | 3145 | 0.130 |
Why?
|
| INDEL Mutation | 1 | 2017 | 265 | 0.130 |
Why?
|
| Acetaldehyde | 1 | 2016 | 39 | 0.130 |
Why?
|
| Embryonic Stem Cells | 3 | 2013 | 1262 | 0.130 |
Why?
|
| Cysteine Endopeptidases | 2 | 2001 | 552 | 0.130 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 794 | 0.130 |
Why?
|
| Quinazolines | 1 | 2022 | 1371 | 0.130 |
Why?
|
| Gene Expression | 14 | 2018 | 7569 | 0.130 |
Why?
|
| Sister Chromatid Exchange | 3 | 2006 | 60 | 0.130 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 382 | 0.130 |
Why?
|
| Frameshift Mutation | 3 | 2006 | 392 | 0.130 |
Why?
|
| Cytoplasm | 3 | 2001 | 1503 | 0.130 |
Why?
|
| Macromolecular Substances | 5 | 2004 | 1433 | 0.130 |
Why?
|
| Reactive Oxygen Species | 3 | 2010 | 2137 | 0.130 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2006 | 2674 | 0.130 |
Why?
|
| Protein Folding | 2 | 2017 | 870 | 0.130 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 7583 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 3593 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2013 | 717 | 0.130 |
Why?
|
| Thiazoles | 2 | 2022 | 1517 | 0.120 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 428 | 0.120 |
Why?
|
| DNA Polymerase II | 1 | 2015 | 104 | 0.120 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1997 | 304 | 0.120 |
Why?
|
| Plasmids | 6 | 2006 | 2265 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2019 | 10754 | 0.120 |
Why?
|
| Protein Conformation | 8 | 2021 | 3965 | 0.120 |
Why?
|
| Methylation | 1 | 2017 | 1077 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2018 | 2223 | 0.120 |
Why?
|
| Boronic Acids | 3 | 2013 | 915 | 0.120 |
Why?
|
| Cyclin D1 | 1 | 2016 | 451 | 0.120 |
Why?
|
| Glioma | 2 | 2024 | 3452 | 0.120 |
Why?
|
| Metformin | 1 | 2022 | 906 | 0.120 |
Why?
|
| Sumoylation | 1 | 2015 | 83 | 0.120 |
Why?
|
| Uterine Neoplasms | 1 | 2023 | 1420 | 0.120 |
Why?
|
| Deoxyribonucleases | 2 | 2018 | 211 | 0.120 |
Why?
|
| Protein Stability | 2 | 2016 | 578 | 0.120 |
Why?
|
| Protein Subunits | 3 | 2013 | 942 | 0.110 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2013 | 47 | 0.110 |
Why?
|
| Genes, p53 | 1 | 1996 | 712 | 0.110 |
Why?
|
| Radiotherapy | 3 | 2016 | 1497 | 0.110 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2016 | 237 | 0.110 |
Why?
|
| Thrombopoietin | 1 | 1996 | 226 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 2812 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2013 | 349 | 0.110 |
Why?
|
| Pedigree | 4 | 2015 | 4539 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2020 | 1263 | 0.110 |
Why?
|
| Immunologic Memory | 1 | 2000 | 1355 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 1998 | 1348 | 0.110 |
Why?
|
| Cyclin E | 1 | 2013 | 155 | 0.110 |
Why?
|
| Cell Differentiation | 8 | 1997 | 11512 | 0.110 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 655 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 1998 | 1202 | 0.110 |
Why?
|
| DNA Methylation | 6 | 2019 | 4392 | 0.110 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2013 | 95 | 0.100 |
Why?
|
| Male | 36 | 2021 | 360402 | 0.100 |
Why?
|
| Coumarins | 2 | 2016 | 118 | 0.100 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2019 | 1692 | 0.100 |
Why?
|
| Granulocytes | 3 | 2005 | 551 | 0.100 |
Why?
|
| Genetic Testing | 2 | 2023 | 3533 | 0.100 |
Why?
|
| Disease-Free Survival | 4 | 2016 | 6807 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 1996 | 4340 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 4 | 1994 | 9171 | 0.100 |
Why?
|
| Polycythemia | 4 | 1994 | 124 | 0.100 |
Why?
|
| Enzyme Activation | 8 | 2013 | 3591 | 0.100 |
Why?
|
| Interleukin-13 | 1 | 1995 | 392 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1997 | 1779 | 0.100 |
Why?
|
| Urothelium | 1 | 2014 | 269 | 0.100 |
Why?
|
| Amino Acid Motifs | 1 | 2015 | 927 | 0.100 |
Why?
|
| Conserved Sequence | 3 | 2014 | 1162 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 2020 | 0.100 |
Why?
|
| Receptors, KIR3DL1 | 3 | 1996 | 26 | 0.100 |
Why?
|
| Amino Acids, Dicarboxylic | 1 | 2011 | 23 | 0.100 |
Why?
|
| Infertility | 2 | 2013 | 654 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 2 | 2006 | 120 | 0.100 |
Why?
|
| Stress, Physiological | 2 | 2017 | 1403 | 0.100 |
Why?
|
| Cyclopentanes | 1 | 2012 | 87 | 0.100 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2011 | 81 | 0.100 |
Why?
|
| Interleukin-10 | 2 | 1995 | 1171 | 0.090 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 88 | 0.090 |
Why?
|
| Crosses, Genetic | 2 | 2009 | 750 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 360 | 0.090 |
Why?
|
| Lectins, C-Type | 3 | 2000 | 584 | 0.090 |
Why?
|
| Leukemia | 2 | 2013 | 1520 | 0.090 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 1827 | 0.090 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 18220 | 0.090 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2011 | 70 | 0.090 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 1394 | 0.090 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 1990 | 50 | 0.090 |
Why?
|
| Tandem Repeat Sequences | 1 | 2011 | 180 | 0.090 |
Why?
|
| Genes, ras | 1 | 2013 | 654 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2014 | 314 | 0.090 |
Why?
|
| Replication Protein A | 1 | 2010 | 53 | 0.090 |
Why?
|
| Protein Interaction Domains and Motifs | 3 | 2019 | 451 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 4 | 2019 | 5780 | 0.090 |
Why?
|
| Globins | 4 | 1995 | 405 | 0.090 |
Why?
|
| Adult | 20 | 2023 | 220995 | 0.090 |
Why?
|
| Child | 13 | 2022 | 80089 | 0.090 |
Why?
|
| Epoxy Compounds | 4 | 2003 | 137 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 1994 | 496 | 0.090 |
Why?
|
| Antigen-Presenting Cells | 1 | 1993 | 963 | 0.080 |
Why?
|
| Escherichia coli Proteins | 1 | 1996 | 1064 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 306 | 0.080 |
Why?
|
| Oncogene Proteins | 1 | 2013 | 718 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1990 | 350 | 0.080 |
Why?
|
| Germ Cells | 1 | 2013 | 634 | 0.080 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 352 | 0.080 |
Why?
|
| Child, Preschool | 8 | 2020 | 42193 | 0.080 |
Why?
|
| Tryptophan | 2 | 2014 | 482 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 7 | 1993 | 1058 | 0.080 |
Why?
|
| DNA Mutational Analysis | 6 | 2020 | 4110 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 1612 | 0.080 |
Why?
|
| MicroRNAs | 2 | 2016 | 3802 | 0.080 |
Why?
|
| Prognosis | 6 | 2022 | 29601 | 0.080 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2003 | 888 | 0.080 |
Why?
|
| Epistasis, Genetic | 1 | 2011 | 350 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2016 | 2467 | 0.080 |
Why?
|
| Cell Fractionation | 2 | 2002 | 249 | 0.080 |
Why?
|
| Middle Aged | 21 | 2023 | 220603 | 0.080 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2008 | 85 | 0.080 |
Why?
|
| Aged, 80 and over | 9 | 2023 | 58919 | 0.080 |
Why?
|
| Two-Hybrid System Techniques | 3 | 2012 | 460 | 0.080 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 13383 | 0.080 |
Why?
|
| Genetic Heterogeneity | 2 | 2002 | 733 | 0.080 |
Why?
|
| Structure-Activity Relationship | 5 | 2016 | 3074 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 3 | 2002 | 1077 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-raf | 3 | 1997 | 205 | 0.080 |
Why?
|
| Genetic Variation | 3 | 2016 | 6561 | 0.080 |
Why?
|
| Evolution, Molecular | 1 | 2016 | 1880 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 619 | 0.070 |
Why?
|
| Immunoprecipitation | 2 | 2010 | 876 | 0.070 |
Why?
|
| STAT5 Transcription Factor | 5 | 2001 | 265 | 0.070 |
Why?
|
| Carbazoles | 1 | 2009 | 220 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 1998 | 140 | 0.070 |
Why?
|
| Dacarbazine | 2 | 2009 | 559 | 0.070 |
Why?
|
| Chromosome Mapping | 5 | 1997 | 4611 | 0.070 |
Why?
|
| Camptothecin | 1 | 2011 | 591 | 0.070 |
Why?
|
| Aged | 15 | 2023 | 169092 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 4569 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2010 | 3115 | 0.070 |
Why?
|
| Genome, Human | 2 | 2019 | 4421 | 0.070 |
Why?
|
| Genetic Vectors | 3 | 2002 | 3392 | 0.070 |
Why?
|
| Carmustine | 1 | 2007 | 137 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 2 | 2010 | 2063 | 0.070 |
Why?
|
| Retroviridae Infections | 2 | 2000 | 147 | 0.070 |
Why?
|
| Androstadienes | 2 | 2006 | 348 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 4570 | 0.070 |
Why?
|
| Molecular Weight | 6 | 1994 | 2185 | 0.070 |
Why?
|
| Protein Isoforms | 3 | 2016 | 1697 | 0.070 |
Why?
|
| Organ Specificity | 2 | 2010 | 1964 | 0.070 |
Why?
|
| Homeostasis | 2 | 2008 | 3321 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2011 | 1172 | 0.070 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1997 | 114 | 0.070 |
Why?
|
| Sequence Alignment | 4 | 2009 | 2178 | 0.070 |
Why?
|
| SUMO-1 Protein | 1 | 2006 | 35 | 0.070 |
Why?
|
| Nijmegen Breakage Syndrome | 1 | 2005 | 4 | 0.070 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 1365 | 0.070 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 210 | 0.070 |
Why?
|
| Precipitin Tests | 4 | 2002 | 813 | 0.070 |
Why?
|
| Genes | 4 | 1990 | 1823 | 0.070 |
Why?
|
| Epitopes | 3 | 2001 | 2501 | 0.060 |
Why?
|
| Time Factors | 7 | 2014 | 39908 | 0.060 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2007 | 506 | 0.060 |
Why?
|
| Binding, Competitive | 2 | 2000 | 1141 | 0.060 |
Why?
|
| Genotype | 5 | 2022 | 12977 | 0.060 |
Why?
|
| Threonine | 1 | 2006 | 271 | 0.060 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2011 | 557 | 0.060 |
Why?
|
| Clone Cells | 5 | 1996 | 1657 | 0.060 |
Why?
|
| Zebrafish | 3 | 2021 | 3005 | 0.060 |
Why?
|
| Guanine | 1 | 2007 | 278 | 0.060 |
Why?
|
| Treatment Outcome | 8 | 2020 | 64572 | 0.060 |
Why?
|
| Alkylating Agents | 1 | 2006 | 133 | 0.060 |
Why?
|
| Embryo, Nonmammalian | 1 | 2009 | 905 | 0.060 |
Why?
|
| Drosophila melanogaster | 2 | 2009 | 1712 | 0.060 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2006 | 199 | 0.060 |
Why?
|
| Antigens, CD | 4 | 2003 | 3998 | 0.060 |
Why?
|
| Chromosome Fragile Sites | 1 | 2005 | 26 | 0.060 |
Why?
|
| Cricetinae | 5 | 2009 | 2424 | 0.060 |
Why?
|
| Mice, Mutant Strains | 3 | 2021 | 1748 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 6 | 1998 | 3730 | 0.060 |
Why?
|
| Cytokines | 6 | 2011 | 7373 | 0.060 |
Why?
|
| Ovary | 3 | 2020 | 959 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2010 | 1329 | 0.060 |
Why?
|
| Mutant Proteins | 1 | 2007 | 489 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 5838 | 0.060 |
Why?
|
| Cohort Studies | 8 | 2023 | 41464 | 0.060 |
Why?
|
| Bacterial Proteins | 2 | 2005 | 3842 | 0.060 |
Why?
|
| Blotting, Northern | 2 | 1997 | 1545 | 0.060 |
Why?
|
| Mosaicism | 2 | 2006 | 474 | 0.060 |
Why?
|
| Indazoles | 2 | 2020 | 304 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2021 | 2625 | 0.060 |
Why?
|
| Gene Knockout Techniques | 2 | 2018 | 802 | 0.060 |
Why?
|
| Isoquinolines | 1 | 2006 | 352 | 0.060 |
Why?
|
| Immune Sera | 2 | 1998 | 605 | 0.060 |
Why?
|
| Coenzymes | 1 | 2024 | 102 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2011 | 1189 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2018 | 10072 | 0.060 |
Why?
|
| Glycoproteins | 1 | 1992 | 2200 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 39062 | 0.060 |
Why?
|
| Benzazepines | 1 | 2006 | 310 | 0.060 |
Why?
|
| Thrombocythemia, Essential | 1 | 2005 | 113 | 0.060 |
Why?
|
| Drug Synergism | 3 | 2019 | 1756 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2006 | 433 | 0.060 |
Why?
|
| Culture Media, Conditioned | 2 | 2016 | 522 | 0.060 |
Why?
|
| Dipyridamole | 1 | 2003 | 140 | 0.050 |
Why?
|
| Predictive Value of Tests | 4 | 2012 | 15250 | 0.050 |
Why?
|
| Blotting, Southern | 4 | 2001 | 777 | 0.050 |
Why?
|
| Dobutamine | 1 | 2003 | 116 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 4 | 2016 | 6074 | 0.050 |
Why?
|
| Adolescent | 7 | 2020 | 88247 | 0.050 |
Why?
|
| src Homology Domains | 3 | 2001 | 361 | 0.050 |
Why?
|
| Interphase | 1 | 1983 | 227 | 0.050 |
Why?
|
| Histone Chaperones | 1 | 2003 | 84 | 0.050 |
Why?
|
| Primary Myelofibrosis | 1 | 2005 | 209 | 0.050 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 5811 | 0.050 |
Why?
|
| Interferon-alpha | 2 | 1997 | 901 | 0.050 |
Why?
|
| Serine | 1 | 2006 | 830 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2007 | 1130 | 0.050 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2022 | 77 | 0.050 |
Why?
|
| Trioxsalen | 1 | 2001 | 2 | 0.050 |
Why?
|
| Gene Products, env | 3 | 1992 | 250 | 0.050 |
Why?
|
| Indoles | 2 | 2011 | 1830 | 0.050 |
Why?
|
| Phosphotyrosine | 3 | 2001 | 456 | 0.050 |
Why?
|
| Oncogenes | 2 | 2021 | 1220 | 0.050 |
Why?
|
| Genes, cdc | 1 | 2002 | 114 | 0.050 |
Why?
|
| Phosphoserine | 1 | 2002 | 203 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2003 | 346 | 0.050 |
Why?
|
| CRADD Signaling Adaptor Protein | 1 | 2021 | 6 | 0.050 |
Why?
|
| Spleen | 2 | 2001 | 2286 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2006 | 2261 | 0.050 |
Why?
|
| Jurkat Cells | 2 | 2019 | 740 | 0.050 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2001 | 99 | 0.050 |
Why?
|
| Brain Stem Neoplasms | 1 | 2003 | 189 | 0.050 |
Why?
|
| Anemia, Aplastic | 1 | 2003 | 230 | 0.050 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2021 | 33 | 0.050 |
Why?
|
| Mevalonic Acid | 1 | 2021 | 46 | 0.050 |
Why?
|
| Rabbits | 3 | 2001 | 4770 | 0.050 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2005 | 547 | 0.050 |
Why?
|
| Histone Acetyltransferases | 1 | 2003 | 335 | 0.050 |
Why?
|
| Spermatocytes | 1 | 2001 | 40 | 0.050 |
Why?
|
| Systole | 1 | 2003 | 935 | 0.050 |
Why?
|
| Tonsillar Neoplasms | 1 | 2001 | 50 | 0.050 |
Why?
|
| Synaptonemal Complex | 1 | 2001 | 24 | 0.050 |
Why?
|
| COS Cells | 2 | 2000 | 1130 | 0.050 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2021 | 101 | 0.050 |
Why?
|
| Protein Transport | 1 | 2007 | 1966 | 0.050 |
Why?
|
| Amino Acid Substitution | 3 | 2002 | 1739 | 0.050 |
Why?
|
| Hybrid Cells | 3 | 2001 | 422 | 0.050 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2002 | 138 | 0.050 |
Why?
|
| Wilms Tumor | 1 | 2003 | 379 | 0.050 |
Why?
|
| U937 Cells | 1 | 2021 | 261 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2023 | 629 | 0.040 |
Why?
|
| Genome | 1 | 2009 | 1737 | 0.040 |
Why?
|
| Nuclear Localization Signals | 1 | 2000 | 77 | 0.040 |
Why?
|
| Cell Membrane | 5 | 1994 | 3680 | 0.040 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2001 | 164 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2003 | 693 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2002 | 441 | 0.040 |
Why?
|
| Flow Cytometry | 5 | 2004 | 5863 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2012 | 1851 | 0.040 |
Why?
|
| DNA, Recombinant | 1 | 2000 | 455 | 0.040 |
Why?
|
| L-Selectin | 1 | 2000 | 211 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2023 | 627 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 4 | 2011 | 6188 | 0.040 |
Why?
|
| Genes, Recessive | 2 | 2000 | 623 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 7995 | 0.040 |
Why?
|
| Siblings | 1 | 2003 | 824 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2012 | 3027 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2002 | 370 | 0.040 |
Why?
|
| K562 Cells | 1 | 2021 | 641 | 0.040 |
Why?
|
| Carcinoma | 1 | 2010 | 2328 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2006 | 1614 | 0.040 |
Why?
|
| Gene Library | 3 | 2014 | 1055 | 0.040 |
Why?
|
| Growth Substances | 1 | 2001 | 768 | 0.040 |
Why?
|
| Radioimmunoassay | 2 | 1992 | 861 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 973 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 1999 | 364 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2001 | 704 | 0.040 |
Why?
|
| Meiosis | 1 | 2001 | 327 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 678 | 0.040 |
Why?
|
| Antigens, Nuclear | 2 | 2012 | 184 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2003 | 610 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1997 | 489 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2000 | 601 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 1008 | 0.040 |
Why?
|
| Medulloblastoma | 1 | 2003 | 677 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1700 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 3514 | 0.040 |
Why?
|
| Janus Kinase 1 | 2 | 1996 | 107 | 0.040 |
Why?
|
| Inflammation | 1 | 1998 | 10759 | 0.040 |
Why?
|
| Response Elements | 1 | 1999 | 309 | 0.040 |
Why?
|
| Membrane Glycoproteins | 3 | 1998 | 3688 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2000 | 897 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 4739 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 1986 | 2690 | 0.040 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 1985 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2000 | 435 | 0.040 |
Why?
|
| Neutropenia | 2 | 2011 | 885 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 336 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2013 | 465 | 0.040 |
Why?
|
| Enzyme Assays | 1 | 2018 | 104 | 0.040 |
Why?
|
| Species Specificity | 2 | 1993 | 2410 | 0.040 |
Why?
|
| Chromosome Inversion | 1 | 1998 | 120 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1998 | 1797 | 0.040 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 1997 | 46 | 0.040 |
Why?
|
| Allelic Imbalance | 1 | 2017 | 77 | 0.040 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 1996 | 21 | 0.040 |
Why?
|
| Observer Variation | 1 | 2003 | 2607 | 0.040 |
Why?
|
| Indolizines | 1 | 2016 | 30 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2006 | 1836 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 4910 | 0.030 |
Why?
|
| GRB2 Adaptor Protein | 1 | 1997 | 101 | 0.030 |
Why?
|
| CHO Cells | 2 | 2001 | 1387 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2358 | 0.030 |
Why?
|
| Cyclic N-Oxides | 1 | 2016 | 72 | 0.030 |
Why?
|
| Pyridinium Compounds | 1 | 2016 | 81 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2000 | 571 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 6927 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 3794 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 1997 | 269 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 883 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 1723 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2001 | 1057 | 0.030 |
Why?
|
| Stem Cell Factor | 1 | 1996 | 195 | 0.030 |
Why?
|
| Cricetulus | 3 | 2009 | 814 | 0.030 |
Why?
|
| Superantigens | 1 | 1996 | 126 | 0.030 |
Why?
|
| Interferons | 1 | 2020 | 702 | 0.030 |
Why?
|
| Abnormalities, Multiple | 1 | 2003 | 1422 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2006 | 1977 | 0.030 |
Why?
|
| Neomycin | 1 | 1996 | 92 | 0.030 |
Why?
|
| Receptors, KIR2DL3 | 1 | 1995 | 15 | 0.030 |
Why?
|
| Interleukin-15 | 1 | 1997 | 185 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 1997 | 243 | 0.030 |
Why?
|
| Receptors, KIR3DS1 | 1 | 1995 | 9 | 0.030 |
Why?
|
| Biological Transport | 1 | 2000 | 2089 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 11107 | 0.030 |
Why?
|
| Counseling | 1 | 2023 | 1538 | 0.030 |
Why?
|
| Introns | 1 | 2018 | 968 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 3634 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2020 | 1087 | 0.030 |
Why?
|
| Ligands | 3 | 1998 | 3268 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2000 | 1864 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1998 | 1759 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 11118 | 0.030 |
Why?
|
| Radiation | 1 | 2015 | 49 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1994 | 817 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2016 | 661 | 0.030 |
Why?
|
| Twins, Monozygotic | 1 | 2017 | 470 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 12043 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2021 | 2048 | 0.030 |
Why?
|
| Young Adult | 4 | 2023 | 59191 | 0.030 |
Why?
|
| Phosphates | 1 | 1998 | 769 | 0.030 |
Why?
|
| Zebrafish Proteins | 1 | 2021 | 1013 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2000 | 1185 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2016 | 427 | 0.030 |
Why?
|
| Cyanoacrylates | 1 | 2015 | 46 | 0.030 |
Why?
|
| Hemagglutinins, Viral | 1 | 1994 | 66 | 0.030 |
Why?
|
| Enterotoxins | 1 | 1996 | 366 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2016 | 454 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2017 | 397 | 0.030 |
Why?
|
| Consensus | 1 | 2024 | 3117 | 0.030 |
Why?
|
| Proteome | 1 | 2024 | 1857 | 0.030 |
Why?
|
| Reference Values | 1 | 2001 | 4919 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 2188 | 0.030 |
Why?
|
| Codon | 1 | 1996 | 600 | 0.030 |
Why?
|
| Clonal Anergy | 1 | 1994 | 169 | 0.030 |
Why?
|
| Pimozide | 1 | 2013 | 21 | 0.030 |
Why?
|
| Survival Rate | 2 | 2020 | 12719 | 0.030 |
Why?
|
| Erythrocytes | 3 | 1994 | 2410 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1994 | 1738 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2020 | 960 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 2527 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1996 | 638 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2006 | 2292 | 0.030 |
Why?
|
| Lentivirus | 1 | 2016 | 507 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2000 | 1347 | 0.030 |
Why?
|
| Muscles | 1 | 2018 | 1573 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 8516 | 0.030 |
Why?
|
| Substrate Specificity | 2 | 2016 | 1790 | 0.030 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1993 | 340 | 0.030 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1994 | 158 | 0.030 |
Why?
|
| Dwarfism | 1 | 1994 | 138 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 1986 | 3026 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1993 | 359 | 0.030 |
Why?
|
| Benzoquinones | 1 | 2013 | 198 | 0.030 |
Why?
|
| Disease Management | 1 | 2003 | 2506 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2003 | 2110 | 0.030 |
Why?
|
| Melanoma | 1 | 2011 | 5696 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 2863 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2003 | 2118 | 0.030 |
Why?
|
| HLA Antigens | 1 | 1998 | 1327 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 321 | 0.030 |
Why?
|
| Phenylalanine | 1 | 2014 | 365 | 0.030 |
Why?
|
| China | 1 | 2018 | 2374 | 0.020 |
Why?
|
| Restriction Mapping | 2 | 1990 | 851 | 0.020 |
Why?
|
| Macrophages | 2 | 2020 | 5758 | 0.020 |
Why?
|
| Methionine | 1 | 1994 | 572 | 0.020 |
Why?
|
| Lactams, Macrocyclic | 1 | 2013 | 318 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 662 | 0.020 |
Why?
|
| Caffeine | 1 | 1996 | 699 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2012 | 95 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 1788 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 2013 | 0.020 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 1994 | 227 | 0.020 |
Why?
|
| Exosomes | 1 | 2016 | 424 | 0.020 |
Why?
|
| Piperidines | 1 | 2020 | 1655 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 1998 | 2546 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2012 | 428 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2003 | 3796 | 0.020 |
Why?
|
| Muridae | 1 | 1990 | 56 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2012 | 544 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 6473 | 0.020 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2011 | 113 | 0.020 |
Why?
|
| Cattle | 1 | 1997 | 3841 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1088 | 0.020 |
Why?
|
| Risk Factors | 3 | 2014 | 74128 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 432 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2011 | 397 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2013 | 748 | 0.020 |
Why?
|
| Radiometry | 1 | 2016 | 812 | 0.020 |
Why?
|
| Genes, env | 1 | 1990 | 95 | 0.020 |
Why?
|
| Neoplasms, Experimental | 2 | 2011 | 1226 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2003 | 1085 | 0.020 |
Why?
|
| Tyrosine | 2 | 1992 | 1440 | 0.020 |
Why?
|
| Endotoxemia | 1 | 2011 | 196 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 4309 | 0.020 |
Why?
|
| Transformation, Bacterial | 1 | 2010 | 76 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2003 | 6346 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2012 | 221 | 0.020 |
Why?
|
| Gamma Rays | 2 | 2001 | 318 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 11069 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1993 | 1248 | 0.020 |
Why?
|
| Testis | 1 | 1993 | 792 | 0.020 |
Why?
|
| Staphylococcus aureus | 2 | 1995 | 1457 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2003 | 5486 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 2 | 1992 | 1132 | 0.020 |
Why?
|
| Endotoxins | 1 | 2011 | 520 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 4365 | 0.020 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2009 | 32 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1993 | 1606 | 0.020 |
Why?
|
| Fibrosis | 1 | 2016 | 2047 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2011 | 246 | 0.020 |
Why?
|
| Peptide Fragments | 2 | 2001 | 5109 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 1745 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 2447 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1996 | 1745 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 2 | 1998 | 30 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 9526 | 0.020 |
Why?
|
| Proteomics | 1 | 2022 | 3836 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 2 | 1998 | 35 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 2 | 1998 | 57 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 1990 | 725 | 0.020 |
Why?
|
| Protein Denaturation | 2 | 2001 | 242 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 1635 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 933 | 0.020 |
Why?
|
| Strongylocentrotus purpuratus | 1 | 2007 | 5 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 1989 | 0.020 |
Why?
|
| Forecasting | 1 | 1996 | 2924 | 0.020 |
Why?
|
| Infant | 4 | 2018 | 36157 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 2010 | 0.020 |
Why?
|
| Immunosorbent Techniques | 2 | 2001 | 174 | 0.020 |
Why?
|
| Autoantigens | 1 | 2011 | 888 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1991 | 790 | 0.020 |
Why?
|
| Monocytes | 2 | 1994 | 2565 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 4252 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 1892 | 0.020 |
Why?
|
| Endocytosis | 1 | 1991 | 955 | 0.020 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 733 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 2252 | 0.020 |
Why?
|
| Bromodeoxyuridine | 2 | 1984 | 310 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 20077 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2011 | 858 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 1129 | 0.020 |
Why?
|
| Elbow | 1 | 2006 | 130 | 0.020 |
Why?
|
| Family Health | 2 | 2005 | 1253 | 0.020 |
Why?
|
| Aphidicolin | 1 | 2005 | 37 | 0.020 |
Why?
|
| Pancytopenia | 1 | 2006 | 102 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1990 | 2340 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 5822 | 0.020 |
Why?
|
| Incidence | 1 | 2003 | 21339 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2006 | 23974 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2013 | 2481 | 0.010 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 9417 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1990 | 2601 | 0.010 |
Why?
|
| Bisbenzimidazole | 1 | 1983 | 13 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 880 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 2005 | 282 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2006 | 461 | 0.010 |
Why?
|
| Viral Proteins | 1 | 1991 | 1799 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2006 | 1229 | 0.010 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2003 | 43 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 2827 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1996 | 4745 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2005 | 836 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 1884 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1998 | 9310 | 0.010 |
Why?
|
| Pyridines | 1 | 2015 | 2875 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 3776 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 531 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 2208 | 0.010 |
Why?
|
| Lysine | 1 | 2007 | 993 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1998 | 1349 | 0.010 |
Why?
|
| Bone Diseases | 1 | 2006 | 418 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 1983 | 299 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 3769 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 2001 | 129 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1983 | 1301 | 0.010 |
Why?
|
| Leupeptins | 1 | 2001 | 113 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2000 | 26183 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2006 | 1835 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 1662 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 1171 | 0.010 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2001 | 142 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 458 | 0.010 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 2 | 1991 | 195 | 0.010 |
Why?
|
| Bleomycin | 1 | 2001 | 494 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2000 | 329 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 3031 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1989 | 1248 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 12966 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2010 | 2553 | 0.010 |
Why?
|
| Cell Fusion | 1 | 2000 | 294 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1980 | 550 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1996 | 7847 | 0.010 |
Why?
|
| Drosophila Proteins | 2 | 2001 | 1698 | 0.010 |
Why?
|
| G-Quadruplexes | 1 | 2001 | 143 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2011 | 5671 | 0.010 |
Why?
|
| Genes, abl | 1 | 1998 | 69 | 0.010 |
Why?
|
| Syndrome | 1 | 2005 | 3268 | 0.010 |
Why?
|
| Sheep | 1 | 2001 | 1436 | 0.010 |
Why?
|
| Recurrence | 1 | 2010 | 8426 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1996 | 15829 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2001 | 901 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 1265 | 0.010 |
Why?
|
| Kidney | 2 | 2010 | 7044 | 0.010 |
Why?
|
| Receptors, Interleukin-5 | 1 | 1997 | 20 | 0.010 |
Why?
|
| HLA-C Antigens | 1 | 1997 | 140 | 0.010 |
Why?
|
| Lung | 1 | 2016 | 9999 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 12448 | 0.010 |
Why?
|
| HLA-A Antigens | 1 | 1997 | 223 | 0.010 |
Why?
|
| Calcium | 1 | 1990 | 5717 | 0.010 |
Why?
|
| Protein Sorting Signals | 1 | 1998 | 278 | 0.010 |
Why?
|
| Interferon-Stimulated Gene Factor 3 | 1 | 1996 | 10 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1997 | 412 | 0.010 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 1996 | 17 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1998 | 328 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 1404 | 0.010 |
Why?
|
| STAT2 Transcription Factor | 1 | 1996 | 27 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 306 | 0.010 |
Why?
|
| Suppression, Genetic | 1 | 1997 | 190 | 0.010 |
Why?
|
| Adenovirus E1A Proteins | 1 | 1996 | 74 | 0.010 |
Why?
|
| Spodoptera | 1 | 1996 | 141 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 1996 | 146 | 0.010 |
Why?
|
| Adenosine Triphosphate | 2 | 1992 | 1988 | 0.010 |
Why?
|
| Lymphoma | 1 | 2005 | 1899 | 0.010 |
Why?
|
| Janus Kinases | 1 | 1997 | 248 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 2006 | 1657 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1996 | 619 | 0.010 |
Why?
|
| Lectins | 1 | 1997 | 489 | 0.010 |
Why?
|
| Blood Donors | 1 | 1997 | 345 | 0.010 |
Why?
|
| Receptors, Thrombopoietin | 1 | 1996 | 160 | 0.010 |
Why?
|
| HLA-DR7 Antigen | 1 | 1994 | 27 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 1996 | 332 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2001 | 2218 | 0.010 |
Why?
|
| Solubility | 1 | 1996 | 1089 | 0.010 |
Why?
|
| Melanins | 1 | 1997 | 289 | 0.010 |
Why?
|
| Janus Kinase 3 | 1 | 1994 | 76 | 0.010 |
Why?
|
| Guanidine | 1 | 1994 | 35 | 0.010 |
Why?
|
| Disease Progression | 1 | 2011 | 13495 | 0.010 |
Why?
|
| Myelin P2 Protein | 1 | 1993 | 20 | 0.010 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1993 | 74 | 0.010 |
Why?
|
| Guanidines | 1 | 1994 | 194 | 0.010 |
Why?
|
| Aging | 1 | 2012 | 8700 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1994 | 532 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 7236 | 0.010 |
Why?
|
| Diphosphoglyceric Acids | 1 | 1992 | 31 | 0.010 |
Why?
|
| 2,3-Diphosphoglycerate | 1 | 1992 | 13 | 0.010 |
Why?
|
| Bloodletting | 1 | 1992 | 22 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2003 | 3606 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1996 | 1084 | 0.010 |
Why?
|
| Megakaryocytes | 1 | 1996 | 566 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1992 | 283 | 0.010 |
Why?
|
| Skin | 1 | 2006 | 4472 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1993 | 410 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 1989 | 4671 | 0.010 |
Why?
|
| Urea | 1 | 1994 | 443 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 15908 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1996 | 1642 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1997 | 1175 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1991 | 452 | 0.010 |
Why?
|
| Protein Multimerization | 1 | 1996 | 982 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 2000 | 1167 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 1994 | 558 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 5074 | 0.010 |
Why?
|
| Endopeptidase K | 1 | 1990 | 23 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1992 | 346 | 0.010 |
Why?
|
| Hexosaminidases | 1 | 1990 | 45 | 0.010 |
Why?
|
| GATA1 Transcription Factor | 1 | 1991 | 296 | 0.010 |
Why?
|
| Liver | 1 | 2006 | 7512 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 416 | 0.010 |
Why?
|
| Erythroblasts | 1 | 1990 | 142 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 1993 | 730 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1990 | 384 | 0.010 |
Why?
|
| DNA Probes | 1 | 1990 | 541 | 0.010 |
Why?
|
| Escherichia coli | 2 | 1998 | 4210 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1993 | 1900 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1991 | 629 | 0.000 |
Why?
|
| Virus Replication | 1 | 1996 | 2427 | 0.000 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 4172 | 0.000 |
Why?
|
| Cell Lineage | 1 | 1996 | 2553 | 0.000 |
Why?
|
| HIV Infections | 1 | 1994 | 17342 | 0.000 |
Why?
|
| Interleukin-6 | 1 | 1996 | 3205 | 0.000 |
Why?
|
| Neural Crest | 1 | 1989 | 278 | 0.000 |
Why?
|
| Mediastinal Neoplasms | 1 | 1989 | 401 | 0.000 |
Why?
|
| Lipopolysaccharides | 1 | 1993 | 2202 | 0.000 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1989 | 333 | 0.000 |
Why?
|
| Serine Endopeptidases | 1 | 1990 | 1022 | 0.000 |
Why?
|
| Mitomycins | 1 | 1984 | 46 | 0.000 |
Why?
|
| Pregnancy | 1 | 2006 | 29869 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 20556 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2010 | 80583 | 0.000 |
Why?
|
| Chromosomes | 1 | 1984 | 578 | 0.000 |
Why?
|
| Polynucleotide 5'-Hydroxyl-Kinase | 1 | 1980 | 7 | 0.000 |
Why?
|
| T-Phages | 1 | 1980 | 90 | 0.000 |
Why?
|
| Methods | 1 | 1980 | 1065 | 0.000 |
Why?
|
| Rats | 1 | 1995 | 23716 | 0.000 |
Why?
|
| Cell Movement | 1 | 1989 | 5201 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1980 | 860 | 0.000 |
Why?
|